MIRA
MIRA·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Ample Liquidity
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About MIRA
Mira Pharmaceuticals, Inc.
An early preclinical stage pharmaceutical company focused on the development and commercialization of novel molecular synthetic THC analogs
1200 Brickell Avenue, Suite 1950 #1183, Miami, Florida 33131
--
MIRA Pharmaceuticals, Inc., was founded in September 2020 in Florida. The Company is a biopharmaceutical company in clinical development and is developing its product candidate MIRA1a as a synthetic cannabinoid analog to treat anxiety and chronic pain by targeting cannabinoid type 1 and type 2 (CB 1 and CB 2) receptors. The company is committed to developing and commercializing a new molecularly synthesized THC analog, which is currently under investigation and is commonly used to treat adult patients with anxiety and cognitive decline associated with early dementia. The company's drug candidate MIRA1a, if approved by the FDA, could make significant progress in the treatment of neuropsychiatric, inflammatory and neurological diseases and disorders.
Company Financials
EPS
MIRA has released its 2025 Q3 earnings. EPS was reported at -1.18, versus the expected -0.08, missing expectations. The chart below visualizes how MIRA has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
